EEF1A1P19: A Drug Target / Disease Biomarker (G100421796)

Target Name: EEF1A1P19

NCBI ID: G100421796

EEF1A1P19

Other Name(s): eukaryotic translation elongation factor 1 alpha 1 pseudogene 19 | Eukaryotic translation elongation factor 1 alpha 1 pseudogene 19

EEF1A1P19: A Drug Target / Disease Biomarker

EEF1A1P19 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. Its unique structure and location in the body make it an attractive candidate for drug targeting.

One of the key features of EEF1A1P19 is its expression pattern. It is highly expressed in the brain and appears to be enriched in the neural tissue. This is important because many diseases, including neurodegenerative disorders, involve damage to the brain. By targeting EEF1A1P19, researchers may be able to develop new treatments for these conditions.

Another feature of EEF1A1P19 is its localization in the body. It is primarily expressed in the peri-glial tissue, which is the surrounding tissue that surrounds each nerve cell. This makes it an ideal target for drugs that can modulate the immune response or the inflammatory response.

EEF1A1P19's unique expression pattern and localization make it an intriguing candidate for drug targeting. However, more research is needed to fully understand its potential as a drug target.

In conclusion, EEF1A1P19 is a protein that is expressed in various tissues throughout the body and its unique expression pattern and localization make it an attractive candidate for drug targeting. Further research is needed to fully understand its potential as a drug target and to develop new treatments for diseases that involve damage to the brain and surrounding tissue.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 19

The "EEF1A1P19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets